{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mark T"],"funding":["NCI NIH HHS"],"pagination":["654-60"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3626496"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["143(5)"],"pubmed_abstract":["The M-protein is the major reference measure for response in multiple myeloma (MM) and its correct interpretation is key to clinical management. The emergence of oligoclonal banding is recognized as a benign finding in the postautologous stem cell transplantation setting (ASCT) for MM but its significance during non-myeloablative therapy is unknown. In a study of the immunomodulatory combination BiRD, (lenalidomide and dexamethasone with clarithromycin), we frequently detected the emergence of mono- and oligo-clonal immunoglobulins unrelated to the baseline diagnostic M-protein. The new M-proteins seen on serum immunofixation electrophoresis were clearly different in either heavy or light chain component(s) from the original M-spike protein and were termed atypical serum immunofixation pat"],"journal":["British journal of haematology"],"pubmed_title":["Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma."],"pmcid":["PMC3626496"],"funding_grant_id":["K23 CA109260","K23 CA109260-01"],"pubmed_authors":["Agrawal YP","Lent R","Pearse RN","Furman RR","Christos PJ","Matthew S","Lee JW","Cesarman E","Mark T","Coleman M","Wang YL","Niesvizky R","Chen-Kiang S","Mazumdar M","Ely S","Leonard JP","Jayabalan D"],"additional_accession":[]},"is_claimable":false,"name":"Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.","description":"The M-protein is the major reference measure for response in multiple myeloma (MM) and its correct interpretation is key to clinical management. The emergence of oligoclonal banding is recognized as a benign finding in the postautologous stem cell transplantation setting (ASCT) for MM but its significance during non-myeloablative therapy is unknown. In a study of the immunomodulatory combination BiRD, (lenalidomide and dexamethasone with clarithromycin), we frequently detected the emergence of mono- and oligo-clonal immunoglobulins unrelated to the baseline diagnostic M-protein. The new M-proteins seen on serum immunofixation electrophoresis were clearly different in either heavy or light chain component(s) from the original M-spike protein and were termed atypical serum immunofixation pat","dates":{"release":"2008-01-01T00:00:00Z","publication":"2008 Dec","modification":"2025-04-03T23:57:54.966Z","creation":"2019-03-27T01:07:25Z"},"accession":"S-EPMC3626496","cross_references":{"pubmed":["18950461"],"doi":["10.1111/j.1365-2141.2008.07374.x"]}}